Answers are grounded in this paper and cite their sources.
Infusion of autologous HER2-CAR VSTs is safe and can be associated with clinical benefit for patients with progressive glioblastoma. Further evaluation of HER2-CAR VSTs in a phase 2b study is warranted as a single agent or in combination with other immunomodulatory approaches for glioblastoma.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: